mGlu2/3 Receptor Antagonists as Novel Antidepressants.

@article{Chaki2017mGlu23RA,
  title={mGlu2/3 Receptor Antagonists as Novel Antidepressants.},
  author={Shigeyuki Chaki},
  journal={Trends in pharmacological sciences},
  year={2017},
  volume={38 6},
  pages={569-580}
}
Based on the discovery of the robust antidepressant effects of ketamine in patients with depression, including those with treatment-resistant depression, agents acting on the glutamatergic system have drawn much attention as potential novel antidepressants. Among the agents acting on the glutamatergic system, preclinical data have indicated that the group II metabotropic glutamate (mGlu) receptors, mGlu2 and mGlu3, are attractive targets for the development of novel antidepressants. The… CONTINUE READING